Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company said on Thursday.

Uncertainty around President Donald Trump’s proposed tariffs and trade policy is putting businesses on America’s southern border on edge. With stiff duties possibly coming as soon as March 1, it’s forcing companies to put spending and hiring decisions on hold.